EXTENDED REPORT

¹ Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester M13 9PT, UK
² Members of BSRBR Control Centre Consortium (see the appendix)

Correspondence to:
Professor A Silman
ARC Unit, University of Manchester, Manchester, UK; a.silman{at}manchester.ac.uk

Objective: To describe the occurrence of baseline comorbidity in subjects with active rheumatoid arthritis starting treatment with biological agents. Such data are necessary to interpret the reported occurrence of adverse events following treatment.

Methods: Baseline comorbidity was recorded in a large national cohort of patients with rheumatoid arthritis newly starting biological agents. The distribution of the number and types of comorbidities is presented.

Results: In all, 7818 patients treated with biological agents (infliximab 3332, etanercept 3302, adalimumab 1059, anakinra 132) were included in the analysis. Comorbidity was common, with 58% of patients having at least one comorbid condition and 25% having more than one. The most frequent comorbid conditions were hypertension, depression, peptic ulcer disease, and respiratory disease.

Conclusions: In routine use, patients treated with biological agents have high levels of baseline comorbidity, which should influence the interpretation of reported adverse events.

Abbreviations: BSRBR, British Society for Rheumatology Biologics Register; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug

Keywords: biological agent; DMARD; comorbidity; rheumatoid arthritis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hider, S. L., Tanveer, W., Brownfield, A., Mattey, D. L., Packham, J. C. (2009). Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (Oxford) 48: 1152-1154 [Abstract] [Full Text]  
• Potter, C, Hyrich, K L, Tracey, A, Lunt, M, Plant, D, Symmons, D P M, Thomson, W, Worthington, J, Emery, P, Morgan, A W, Wilson, A G, Isaacs, J, Barton, A, BRAGGSS, (2009). Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68: 69-74 [Abstract] [Full Text]  
• Hyrich, K. L., Watson, K. D., Isenberg, D. A., Symmons, D. P. M., on behalf of the BSR Biologics Register, (2008). The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 47: 1441-1443 [Full Text]  
• Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D. (2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47: 1286-1298 [Abstract] [Full Text]  
• Jerram, S., Butt, S., Gadsby, K., Deighton, C. (2008). Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?. Rheumatology (Oxford) 47: 180-182 [Abstract] [Full Text]  
• Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E., van Vollenhoven, R. (2007). Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1462-1466 [Abstract] [Full Text]  
• Sheehy, C., Murphy, E., Barry, M. (2006). Depression in rheumatoid arthritis--underscoring the problem. Rheumatology (Oxford) 45: 1325-1327 [Full Text]  
• Winthrop, K L (2006). Serious infections with antirheumatic therapy: are biologicals worse?. Ann Rheum Dis 65: iii54-iii57 [Abstract] [Full Text]